IBD affects millions of Americans. It's estimated that 130,000 adults and children in New England are living with the disease ...

Dual biologic therapy may serve as a suitable treatment choice for patients with IBD who have not responded to current therapies.

Inflammatory bowel disease is a diverse disease that affects people all over the globe. This diversity in setting and treatment options makes it difficult for researchers to estimate the exact cost of ...

The Dow Jones and S&P 500 posted robust gains Friday afternoon. Nvidia led the Dow and Ulta topped the S&P 500 on the stock ...

HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active ...

A team led by researchers at the University of Toronto has discovered that a compound present in ginger selectively binds to ...

There is insufficient evidence to support exclusive enteral nutrition as an adjunctive therapy for active ulcerative colitis, ...

Achieving cost sustainability in inflammatory bowel disease (IBD) care requires expanding access to cost-effective treatments ...

Ulcerative colitis (UC) is a chronic disease that causes inflammation in the large intestine, affecting between 600,000 and ...

Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.